272 related articles for article (PubMed ID: 26346786)
1. Emerging tumefactive MS after switching therapy from interferon-beta to fingolimod: A case report.
Harirchian MH; Taalimi A; Siroos B
Mult Scler Relat Disord; 2015 Sep; 4(5):400-402. PubMed ID: 26346786
[TBL] [Abstract][Full Text] [Related]
2. Early relapse with tumefactive MS lesion upon initiation of fingolimod therapy.
Boangher S; Goffette S; Van Pesch V; Mespouille P
Acta Neurol Belg; 2016 Mar; 116(1):95-7. PubMed ID: 26071761
[No Abstract] [Full Text] [Related]
3. Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events.
Fragoso YD
Acta Neurol Belg; 2017 Dec; 117(4):821-827. PubMed ID: 28528469
[TBL] [Abstract][Full Text] [Related]
4. Cerebral toxoplasmosis in an MS patient receiving Fingolimod.
Enriquez-Marulanda A; Valderrama-Chaparro J; Parrado L; Diego Vélez J; Maria Granados A; Luis Orozco J; Quiñones J
Mult Scler Relat Disord; 2017 Nov; 18():106-108. PubMed ID: 29141790
[TBL] [Abstract][Full Text] [Related]
5. Tumefactive demyelinating lesions: A comprehensive review.
Algahtani H; Shirah B; Alassiri A
Mult Scler Relat Disord; 2017 May; 14():72-79. PubMed ID: 28619436
[TBL] [Abstract][Full Text] [Related]
6. Severe Exacerbation of Multiple Sclerosis Following Withdrawal of Fingolimod.
Fragoso YD; Adoni T; Gomes S; Goncalves MVM; Parolin LF; Rosa G; Ruocco HH
Clin Drug Investig; 2019 Sep; 39(9):909-913. PubMed ID: 31152369
[TBL] [Abstract][Full Text] [Related]
7. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
[TBL] [Abstract][Full Text] [Related]
8. Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases.
Sánchez P; Meca-Lallana V; Vivancos J
Mult Scler Relat Disord; 2018 Oct; 25():95-98. PubMed ID: 30056362
[TBL] [Abstract][Full Text] [Related]
9. Severe rebound after withdrawal of fingolimod treatment in patients with multiple sclerosis.
Gündüz T; Kürtüncü M; Eraksoy M
Mult Scler Relat Disord; 2017 Jan; 11():1-3. PubMed ID: 28104247
[No Abstract] [Full Text] [Related]
10. A tumefactive demyelinating lesion in a person with MS after five years of fingolimod.
Jeung L; Smits LMG; Hoogervorst ELJ; van Oosten BW; Frequin STFM
Mult Scler Relat Disord; 2020 May; 40():101978. PubMed ID: 32062445
[TBL] [Abstract][Full Text] [Related]
11. Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab.
Bernard-Valnet R; Pignolet B; Biotti D; Ciron J; Lafontan JF; Dumas H; Bonneville F; Brassat D
Mult Scler Relat Disord; 2018 Oct; 25():216-218. PubMed ID: 30114625
[TBL] [Abstract][Full Text] [Related]
12. Tumefactive demyelinating lesions after initiating fingolimod in patient with multiple sclerosis: A case report.
Navardi S; Sahraian MA; Naser Moghadasi A
Rev Neurol (Paris); 2020 May; 176(4):289-290. PubMed ID: 31668286
[No Abstract] [Full Text] [Related]
13. Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study.
Paolicelli D; Manni A; Direnzo V; D'Onghia M; Tortorella C; Zoccolella S; Trojano M
J Clin Pharmacol; 2015 Oct; 55(10):1131-6. PubMed ID: 25903516
[TBL] [Abstract][Full Text] [Related]
14. [Fingolimod].
Hashi Y; Kondo T
Nihon Rinsho; 2015 Sep; 73 Suppl 7():205-11. PubMed ID: 26480701
[No Abstract] [Full Text] [Related]
15. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
[TBL] [Abstract][Full Text] [Related]
16. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
He A; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Girard M; Pucci E; Iuliano G; Alroughani R; Oreja-Guevara C; Fernandez-Bolaños R; Grand'Maison F; Sola P; Spitaleri D; Granella F; Terzi M; Lechner-Scott J; Van Pesch V; Hupperts R; Sánchez-Menoyo JL; Hodgkinson S; Rozsa C; Verheul F; Butzkueven H; Kalincik T;
JAMA Neurol; 2015 Apr; 72(4):405-13. PubMed ID: 25665031
[TBL] [Abstract][Full Text] [Related]
17. Severe disease exacerbations in patients with multiple sclerosis after discontinuing fingolimod.
Członkowska A; Smoliński Ł; Litwin T
Neurol Neurochir Pol; 2017; 51(2):156-162. PubMed ID: 28209440
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?
Carpenter AF; Goodwin SJ; Bornstein PF; Larson AJ; Markus CK
Mult Scler; 2017 Feb; 23(2):297-299. PubMed ID: 28165320
[TBL] [Abstract][Full Text] [Related]
19. Disease Exacerbation after the Cessation of Fingolimod Treatment in Japanese Patients with Multiple Sclerosis.
Sato K; Niino M; Kawashima A; Yamada M; Miyazaki Y; Fukazawa T
Intern Med; 2018 Sep; 57(18):2647-2655. PubMed ID: 29709955
[TBL] [Abstract][Full Text] [Related]
20. Retinal hemorrhages following fingolimod treatment for multiple sclerosis; a case report.
Ueda N; Saida K
BMC Ophthalmol; 2015 Oct; 15():135. PubMed ID: 26481728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
